RSV is spread through droplets in the air when the infected cough or sneeze and can be passed on by touching a surface ...

Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

Respiratory syncytial virus, commonly known as RSV, is a common respiratory infection that affects children and adults. Most children contract RSV before the age of 2. RSV is not usually a serious ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

This 1981 photo provided by the Centers for Disease Control and Prevention (CDC) shows an electron micrograph of Respiratory Syncytial Virus, also known as RSV. (PHOTO: CDC via AP) (ABC NEWS ...

Background: Respiratory syncytial virus (RSV) vaccines have been recommended for US adults aged ≥60 years for nearly one year. However, the extent of vaccination coverage and the factors influencing ...

Two studies published today show more promising evidence that the respiratory syncytial virus (RSV) antibody, nirsevimab, is an effective way to protect infants from illness. Protection against ...

Post-pandemic, two other viruses have now crashed the seasonal party and are currently co-circulating with influenza. RSV (respiratory syncytial virus) and the now-endemic SARS-CoV-2 both increase in ...

Respiratory syncytial virus (RSV) causes cold-like symptoms in most people but can cause more serious problems in some, especially babies and older adults. Almost all children get RSV at least once by ...